Skip to main content
Premium Trial:

Request an Annual Quote

Reinhard Ambros

Reinhard Ambros has joined the board of directors of Synthetic Genomics. He was the global head of the Novartis Venture Fund from 2005 until 2017. Prior to that, he was head of group strategic planning at Novartis and led business development and licensing in the cardiovascular and metabolic disease area for Novartis Pharma. Ambros holds a PhD from the University of Regensburg in Germany.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.